• Saturday, Nov 28, 2020
  • Last Update : 02:08 am

Regeneron announces more positive results for Covid-19 treatment

  • Published at 01:11 pm October 29th, 2020
Coronavirus Vaccine
File photo: A small bottle labeled with a 'Vaccine' sticker is held near a medical syringe in front of displayed 'Coronavirus Covid-19' words in this illustration taken on April 10, 2020 Reuters

REGN-COV2 is a combination of two antibodies, one harvested from a recovered patient and the other from a mouse with a human-like immune system

Regeneron, the US biotech firm that supplied synthetic antibodies to treat President Donald Trump's Covid-19, announced Wednesday it had more positive results to show from an ongoing clinical trial.

The company had previously announced results for 275 people in its late-stage study of non-hospitalized Covid-19 patients on REGN-COV2, and said data from an additional 524 people bore out the trend.

It has already applied for an emergency use authorization for its drug.

"Today's analysis, involving more than 500 additional patients, prospectively confirms that REGN-COV2 can indeed significantly reduce viral load and further shows that these viral reductions are associated with a significant decrease in the need for further medical attention," said the company's president George Yancopoulos.

The trial found no significant difference in results between high dose (8 grams) and low dose (2.4 grams).

The rate of Covid-19 related medical visits was 2.8% in the treatment groups and 6.5% in the placebo arm, a relative risk reduction of 57%.

It also reduced Covid-19 related medical visits by 72% in patients with one or more underlying conditions, including being over 50 years old, obesity, having heart, lung or kidney disease or being immunocompromised.

REGN-COV2 is a combination of two antibodies, one harvested from a recovered patient and the other from a mouse with a human-like immune system.

In related news, an antibody treatment developed by the pharmaceutical firm Eli Lilly showed positive results from a mid-stage clinical trial, whose findings were published in the New England Journal of Medicine.

But only one of the three studied dose groups, 2.8 grams, was found to be effective, and only moderately.

Though these results were modest, the company later modified its study and reported more positive results, which haven't yet been published formally.

The US government said Wednesday it was purchasing 300,000 doses of Lilly's drug, called bamlanivab, at the lowest dose level (0.7 gram).

blogger sharing button blogger
buffer sharing button buffer
diaspora sharing button diaspora
digg sharing button digg
douban sharing button douban
email sharing button email
evernote sharing button evernote
flipboard sharing button flipboard
pocket sharing button getpocket
github sharing button github
gmail sharing button gmail
googlebookmarks sharing button googlebookmarks
hackernews sharing button hackernews
instapaper sharing button instapaper
line sharing button line
linkedin sharing button linkedin
livejournal sharing button livejournal
mailru sharing button mailru
medium sharing button medium
meneame sharing button meneame
messenger sharing button messenger
odnoklassniki sharing button odnoklassniki
pinterest sharing button pinterest
print sharing button print
qzone sharing button qzone
reddit sharing button reddit
refind sharing button refind
renren sharing button renren
skype sharing button skype
snapchat sharing button snapchat
surfingbird sharing button surfingbird
telegram sharing button telegram
tumblr sharing button tumblr
twitter sharing button twitter
vk sharing button vk
wechat sharing button wechat
weibo sharing button weibo
whatsapp sharing button whatsapp
wordpress sharing button wordpress
xing sharing button xing
yahoomail sharing button yahoomail